Company intelligence / Profile preview

Maverick Therapeutics

Brisbane, California, United Statestakedaoncology.com ↗

Ownership: Private
Employees: ~5
Development stage: Phase 1

Overview

Maverick’s lead candidate TAK‑186 (formerly MVC‑101) entered Phase 1/2 trials for EGFR-expressing solid tumors. Preclinical data showed antitumor activity and tumor shrinkage in multiple tumor types. A second candidate TAK‑280 (MVC‑280) was expected to enter clinical trials targeting B7H3-expressing solid tumors. Three additional preclinical programs were in development at the time of acquisition[1][6][8].

Therapeutic areas: Oncology
Modalities: Bispecific antibodies (T-cell engagers)Immunotherapies (conditionally active)
Industry: Biotech

Drug pipeline

2 assets

TAK-186

Phase 1

Indications: EGFR-expressing solid tumors

1 more asset in the full pipeline.

Request access →

Partnerships

Takeda Pharmaceutical Company Limited – initial R&D collaboration with exclusive option to acquire since January 2017; full acquisition completed March/April 2021[3][6].

Beyond the preview

Go deeper on Maverick Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Maverick Therapeutics.

Explore the full profile